Q-omics provides the consensus-scored KRT73 profile across patient tissues and cancer cell-line models. KRT73 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KRT73 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, KRT73 RNA expression shows 10,869 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUAD, and THYM as cancer lineages where KRT73 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT73 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT73 survival associations across molecular data types. KRT73 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT73 RNA expression–survival associations across cancer types. High KRT73 expression shows unfavorable associations in KIRP, DLBC, COAD and LUAD, but favorable associations in CESC and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for KRT73 RNA expression.
This table summarizes KRT73 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KRT73. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT73 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in KIRC and BRCA. The LUAD box plot shows higher KRT73 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p < 0.001).
This table shows molecular features associated with KRT73 in patient tissues and cancer cell lines. In patient samples, KRT73 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT73 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
